XML 186 R129.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial assets and liabilities measured at fair value - Summary of Assets and Liabilities Measured at Fair Value (Details) - EUR (€)
€ in Millions
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Level 1      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value € 5,673 € 6,737 € 10,765
Total financial liabilities measured at fair value 0 0 0
Level 1 | Bayer contingent purchase consideration arising from the acquisition of Genzyme      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | MSD contingent consideration (European vaccines business)      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Shire contingent consideration arising from the acquisition of Translate Bio      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Contingent consideration arising from acquisition of Amunix      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Other contingent consideration arising from business combinations and acquisitions      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 1 | Quoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 467 470 387
Level 1 | Unquoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 1 | Quoted debt securities      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 357 346 329
Level 1 | Unquoted debt securities not meeting the definition of equity instruments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 1 | Contingent consideration relating to divestments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 1 | Financial assets held to meet obligations under deferred compensation plans      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 688 572 512
Level 1 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 1 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 1 | Mutual fund investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 4,161 5,349 9,537
Level 2      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 217 201 206
Total financial liabilities measured at fair value 458 291 326
Level 2 | Bayer contingent purchase consideration arising from the acquisition of Genzyme      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 2 | MSD contingent consideration (European vaccines business)      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 2 | Shire contingent consideration arising from the acquisition of Translate Bio      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 2 | Contingent consideration arising from acquisition of Amunix      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 2 | Other contingent consideration arising from business combinations and acquisitions      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 2 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 121 164 232
Level 2 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 337 127 94
Level 2 | Quoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Unquoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Quoted debt securities      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Unquoted debt securities not meeting the definition of equity instruments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Contingent consideration relating to divestments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Financial assets held to meet obligations under deferred compensation plans      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 2 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 217 201 206
Level 2 | Mutual fund investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 1,717 964 967
Total financial liabilities measured at fair value 641 709 779
Level 3 | Bayer contingent purchase consideration arising from the acquisition of Genzyme      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 26
Level 3 | MSD contingent consideration (European vaccines business)      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 72 127 204
Level 3 | Shire contingent consideration arising from the acquisition of Translate Bio      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 568 441 380
Level 3 | Contingent consideration arising from acquisition of Amunix      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 137 165
Level 3 | Other contingent consideration arising from business combinations and acquisitions      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 1 4 4
Level 3 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 3 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial liabilities measured at fair value 0 0 0
Level 3 | Quoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3 | Unquoted equity investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 1,092 618 549
Level 3 | Quoted debt securities      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3 | Unquoted debt securities not meeting the definition of equity instruments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 339 132 115
Level 3 | Contingent consideration relating to divestments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 286 214 303
Level 3 | Financial assets held to meet obligations under deferred compensation plans      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3 | Non-current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3 | Current derivatives      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value 0 0 0
Level 3 | Mutual fund investments      
Disclosure of information on income statement [line items]      
Total financial assets measured at fair value € 0 € 0 € 0